Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
3 verified discoveries match your filters.
The NHS-Galleri trial's PRIMARY endpoint — a statistically significant reduction in COMBINED stage III and IV cancer diagnoses — was NOT met. Reported secondary findings were more favorable: stage IV…
Primary source cited
Last reviewed
In the prospective, 20,176-participant BLUE-C study, Cologuard Plus (a next-generation multitarget stool DNA test) detected colorectal cancer with 95% sensitivity and correctly identified 94% of participants without colorectal cancer or…
Primary source cited
Last reviewed
Across two validation cohorts, an 18-gene urine test (MPS2) substantially outperformed PSA alone (AUC 0.81–0.82 vs. 0.60) for detecting higher-grade prostate cancer, with modeled reductions in unnecessary biopsies, including in…
Primary source cited
Last reviewed